A systematic review suggests psilocybin and ketamine/esketamine may improve depression through different brain-network effects.
Evidence
This PRISMA systematic review summarized 49 neuroimaging and clinical studies in depressive disorders, mostly on ketamine/esketamine (44 studies) with only 5 on psychedelic tryptamines, spanning randomized, open-label, observational, double-blind, and cross-over designs.
Caveat
The evidence base was heterogeneous and heavily weighted toward ketamine/esketamine, with few psychedelic studies, so mechanistic and comparative conclusions remain preliminary.
Simplified
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are increasingly used to manage . The biological mechanisms set in motion by these compounds are still largely unexplored. Preliminary data indicate modulatory activity of distinct brain networks and selected neurotransmitter pathways (i.e., glutamate, serotonin).
OBJECTIVE: This systematic review investigates functional changes in neural activity generated by these compounds (i.e., LSD, psilocybin, ayahuasca, and DMT or ketamine/esketamine) in depressive disorders. Studies involving different techniques (i.e. Positron Emission Tomography/PET, Single Photon Emission Computed Tomography/SPECT, functional Magnetic Resonance Imaging/fMRI and MRI) were included.
METHOD: A literature search was conducted following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines of 2015. The search was performed using PubMed Web of Science and Scopus databases, taking into consideration publications up to March 2022, without any time restrictions.
RESULTS: The search produced a final set of 49 articles. Most were related to ketamine/esketamine (n = 44). A smaller number (n = 5) pertained to psychedelic tryptamines (one on ayahuasca and four on psilocybin). From the total of 49 studies, 9 were randomized-controlled trials, 25 were open-label studies, 4 were double-blind trials, 8 were observational studies, and 3 cross-over studies.
CONCLUSIONS: Psylocibin seems to reset (DMN) activity, thereby reducing depressive symptoms with long-term and sustainable antidepressant efficacy. Compared to psychedelics, ketamine exhibits a more specific action on networks involving prefrontal areas that act indirectly on the DMN. This effect may help explain ketamine's anti-anhedonic activity and its critical role in increasing cognitive control over emotional stimuli, thus reducing negative mood stages.
Key numbers
49
Study Count
Total number of articles included in the review.
44
Ketamine Studies
Number of studies related to ketamine/esketamine.
5
Psilocybin Studies
Number of studies related to psychedelic tryptamines.
Full Text
We can’t show the full text here under this license.
